Theragenics was originally founded as Nuclear Medicine, Inc. in 1981 by a group of physicists at the Georgia Institute of Technology. The mission of the company was to develop and market radiological pharmaceuticals and devices to fight cancer. In the early years of development, the company’s strategy was to identify those cancers whose cure rates had not improved significantly in the previous two decades, that were consistently diagnosed as inoperable, or that had claimed increasingly more lives and then to develop products to treat them. Accordingly, Theragenics identified three cancers: prostate, liver and brain cancer and embarked on developing products for each of these. In 1988 this strategy was further refined and Theragenics narrowed its focus to prostate and liver cancer treatments. We began diversifying operations in 2005 by acquiring CP Medical, Inc., and have continued to expand with the acquisitions of Galt Medical Corp., NeedleTech Products, Inc., Concert Medical, and Arrotek.